Tag Archives: ZYNE

Zynerba

Zynerba Pharmaceuticals Announces Completion of Enrollment for ZYN002 in Two Phase 2 Clinical Trials for Epilepsy and Osteoarthritis

Zynerba Pharmaceuticals Announces Completion of Enrollment for ZYN002 in Two Phase 2 Clinical Trials for Epilepsy and Osteoarthritis

DEVON, Penn., March 13, 2017 /Weed Wire/ — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it has completed enrollment in the Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in adult epilepsy patients with refractory focal seizures.

Zynerba

Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock

DEVON, Pa., Jan. 19, 2017 /Weed Wire/ — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced the pricing of an underwritten public offering of 2.8 million shares of its common stock at a price of $18.00 per share, with expected gross proceeds to Zynerba of $50.4 million.

Zynerba

Zynerba Pharmaceuticals to Participate in Upcoming Investor Meetings and Conferences

DEVON, Pa., June 1, 2016 /Weed Wire/ — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will participate in various upcoming investor meetings and conferences.

Zynerba

Zynerba Pharmaceuticals Reports First Quarter 2016 Financial Results and Operational Highlights

DEVON, Pa., May 12, 2016 /Weed Wire/ — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today reported financial results for the quarter ended March 31, 2016, and provided an overview of recent operational highlights.

Zynerba

Zynerba Pharmaceuticals to Present at 28th Annual ROTH Conference

DEVON, Pa., March 7, 2016 /Weed Wire/ — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will present at the 28th Annual ROTH Conference.

Zynerba

Zynerba: The Need for Speculative Fortitude

Zynerba presented the status of its research program at BIO Investor Forum. This is a 14-year-old annual biotech gathering, with roughly 600 attendees from 21 countries, and the presentation, in San Francisco, looked likely to be a big event in this company’s development.

Zynerba IPO

Zynerba IPO a Big $275 Million Entry for Cannabinoids

It has been a bit of a dry spell for decent IPOs in the cannabis space. But the rains have come down with the initial public offering of Devon, Pennsylvania-based Zynerba Pharmaceuticals (NASDAQ: ZYNE).


Top